IPO - Profile

Summary

We are a preclinical-stage pharmaceutical company focused on becoming a global leader in pain management by developing and delivering innovative non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. We are developing branded pharmaceutical product candidates with a focus on pain management by using cutting-edge technology to enhance patients’ quality of life.

 We have exclusive global rights to develop, sell and export (among other rights) a proprietary patented nonsteroidal anti-inflammatory Topical Spray Film Delivery Technology for acute musculoskeletal pain (“DSF100” or “EpoladermTM”) and for chronic osteoarthritis of the More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$10.00 1,800,000 Positive High 103.82%

Offering Team

  • Legal counsel
  • Lowenstein Sandler LLP
  • Auditors
  • EisnerAmper LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 16 Feb, 2021

Offer 17 Feb, 2021

Look Ahead

Lock Up Expiry Aug 17, 2021

IPO Terms

Offer Price $10.00
Offer Size 1M

Market Sentiments

Stock Price